PT  - JOURNAL ARTICLE
AU  - Parkin, Georgia M.
AU  - McCarthy, Michael J.
AU  - Thein, Soe H.
AU  - Piccerillo, Hillary L.
AU  - Warikoo, Nisha
AU  - Granger, Douglas A.
AU  - Thomas, Elizabeth A.
TI  - Saliva testing as a means to monitor therapeutic lithium levels in patients with psychiatric disorders: identification of clinical and environmental covariates, and their incorporation into a prediction model
AID  - 10.1101/2021.03.23.21253841
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.23.21253841
4099  - http://medrxiv.org/content/early/2021/03/26/2021.03.23.21253841.short
4100  - http://medrxiv.org/content/early/2021/03/26/2021.03.23.21253841.full
AB  - The narrow therapeutic window of lithium medications necessitates frequent serum monitoring, which can be expensive and inconvenient for the patient. The use of saliva as a biofluid may have advantages over blood, as it is non-invasive, easier to collect, requires less processing, and can be collected without the need for trained personnel. This study investigated the utility of saliva as a longitudinal means of monitoring lithium levels. We measured lithium levels using Inductively-Coupled Plasma Optical Emission Spectrometry (ICP-OES) in n=171 saliva samples collected via the passive drool method, from a multi-center cohort consisting of n=75 patients with bipolar disorder or other psychiatric conditions. We found that saliva and serum levels of lithium were highly correlated (unadjusted Spearman r=0.74, p<0.0001) and that consideration of daily lithium dose, dosing schedule, cotinine-confirmed smoking status and diabetes status could improve this relationship (adjusted Spearman r=0.77, p<0.0001). Using this adjusted intersubject equation to predict an individual’s serum lithium levels from their salivary lithium value, we observed a strong linear correlation between the predicted vs. actual serum lithium levels r=0.70; P<0.0001). Longitudinal samples were collected from patients for up to 18 months from the initial assessment. The saliva/serum ratios across these multiple visits were highly stable for most patients. Variability in the saliva/serum ratios across observations was found to be significantly associated with age. Using the intrasubject saliva/serum ratio from a single prior observation was not better than using the interpatient linear regression equation at predicting the serum lithium levels. However, the using the mean intrasubject ratio calculated from three prior observations could robustly predict serum levels with a predicted vs. actual serum correlation of r=0.90 (p<0.0001). These findings strongly suggest that saliva could be used for lithium monitoring and open the door for the development and implementation of a point-of-care salivary lithium device that could be used at home or in the clinic. We propose that the use of saliva will dramatically improve treatment opportunities for patients with mood disorders.View this table:Data availability statement Anonymized summary data will be shared by reasonable formal request from qualified researchers, subject to a data sharing agreement and in compliance with the requirements of the funding bodies and institutions.Competing Interest StatementDA Granger is founder and Chief Scientific and Strategy Advisor at Salimetrics LLC and Salivabio LLC. These relationships are managed by the policies of the committees on conflict of interest at the Johns Hopkins University School of Medicine and the University of California at Irvine. No other authors declare competing interests. The founding sponsor had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results. Funding StatementThis study was funded by the Elisabeth Severance Prentiss Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Institutional Review Boards at the University of California Irvine (UCI), University of California San Diego (UCSD) and VA San Diego Healthcare System (VASDHS), in accordance with the requirements of the Code of Federal Regulations on the Protection of Human Subjects.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized summary data will be shared by reasonable formal request from qualified researchers, subject to a data sharing agreement and in compliance with the requirements of the funding bodies and institutions.